Bifogade filer
CA240812-insider-trading
Kurs
-2,80%
Kurs
-2,80%
Open
903,00
High
910,00
Low
891,10
Close
892,90
Kursutveckling under dagen för detta pressmeddelande
(DKK).
Likviditet
2 272 MDKK
Likviditet
2 272 MDKK
Rel. mcap
0,09%
Antal aktier
2 532 104
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-11-05 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-06 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-05 | 07:30 | Bokslutskommuniké 2024 |
| 2024-11-06 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-15 | - | X-dag halvårsutdelning NOVO B 3.5 |
| 2024-08-07 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-02 | - | Kvartalsrapport 2024-Q1 |
| 2024-03-22 | - | X-dag halvårsutdelning NOVO B 6.4 |
| 2024-03-21 | - | Årsstämma |
| 2024-01-31 | - | Bokslutskommuniké 2023 |
| 2023-11-02 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-13 | - | Split NOVO B 1:2 |
| 2023-08-18 | - | X-dag halvårsutdelning NOVO B 6 |
| 2023-08-10 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-24 | - | X-dag halvårsutdelning NOVO B 8.15 |
| 2023-03-23 | - | Årsstämma |
| 2023-02-01 | - | Bokslutskommuniké 2022 |
| 2022-11-02 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-12 | - | X-dag halvårsutdelning NOVO B 4.25 |
| 2022-08-04 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-04 | - | Kvartalsrapport 2022-Q1 |
| 2022-03-25 | - | X-dag halvårsutdelning NOVO B 6.9 |
| 2022-03-24 | - | Årsstämma |
| 2022-02-02 | - | Bokslutskommuniké 2021 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-16 | - | X-dag halvårsutdelning NOVO B 3.5 |
| 2021-08-05 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-26 | - | X-dag halvårsutdelning NOVO B 5.85 |
| 2021-03-25 | - | Årsstämma |
| 2021-02-03 | - | Bokslutskommuniké 2020 |
| 2020-10-30 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-14 | - | X-dag halvårsutdelning NOVO B 3.25 |
| 2020-08-06 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-06 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-27 | - | X-dag halvårsutdelning NOVO B 5.35 |
| 2020-03-26 | - | Årsstämma |
| 2020-02-05 | - | Bokslutskommuniké 2019 |
| 2019-11-01 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-16 | - | X-dag halvårsutdelning NOVO B 3 |
| 2019-05-03 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-22 | - | X-dag halvårsutdelning NOVO B 5.15 |
| 2019-03-21 | - | Årsstämma |
| 2019-02-01 | - | Bokslutskommuniké 2018 |
| 2018-08-18 | - | X-dag halvårsutdelning NOVO B 3 |
| 2018-08-17 | - | X-dag halvårsutdelning NOVO B 3 |
| 2018-08-08 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-02 | - | Kvartalsrapport 2018-Q1 |
| 2018-03-23 | - | X-dag halvårsutdelning NOVO B 4.85 |
| 2018-03-22 | - | Årsstämma |
| 2018-02-01 | - | Bokslutskommuniké 2017 |
| 2017-11-01 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | X-dag halvårsutdelning NOVO B 3 |
| 2017-08-09 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-03 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-24 | - | X-dag ordinarie utdelning NOVO B 4.60 DKK |
| 2017-03-23 | - | Årsstämma |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-10-28 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-12 | - | X-dag halvårsutdelning NOVO B 3 |
| 2016-08-05 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-03-21 | - | X-dag halvårsutdelning NOVO B 6.4 |
| 2016-03-18 | - | Årsstämma |
| 2016-02-03 | - | Bokslutskommuniké 2015 |
| 2015-10-29 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-06 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-30 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-20 | - | X-dag ordinarie utdelning NOVO B 5.00 DKK |
| 2015-03-19 | - | Årsstämma |
| 2015-01-30 | - | Bokslutskommuniké 2014 |
| 2014-10-30 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-07 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-01 | - | Kvartalsrapport 2014-Q1 |
| 2014-03-21 | - | X-dag ordinarie utdelning NOVO B 4.50 DKK |
| 2014-03-20 | - | Årsstämma |
| 2014-02-03 | - | Bokslutskommuniké 2013 |
| 2014-01-02 | - | Split NOVO B 1:5 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-08 | - | Kvartalsrapport 2013-Q2 |
| 2013-05-01 | - | Kvartalsrapport 2013-Q1 |
| 2013-03-21 | - | X-dag ordinarie utdelning NOVO B 18.00 DKK |
| 2013-03-20 | - | Årsstämma |
| 2013-02-04 | - | Bokslutskommuniké 2012 |
| 2012-10-31 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-09 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-27 | - | Kvartalsrapport 2012-Q1 |
| 2012-03-22 | - | X-dag ordinarie utdelning NOVO B 14.00 DKK |
| 2012-03-21 | - | Årsstämma |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-04 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-03-24 | - | X-dag ordinarie utdelning NOVO B 10.00 DKK |
| 2011-03-23 | - | Årsstämma |
| 2011-02-02 | - | Bokslutskommuniké 2010 |
| 2010-03-25 | - | X-dag ordinarie utdelning NOVO B 7.50 DKK |
| 2007-12-03 | - | Split NOVO B 1:2 |
| 2001-04-04 | - | Split NOVO B 1:5 |
| 1997-01-02 | - | Split NOVO B 1:2 |
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Large Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
2024-08-12 14:04:34
Bagsværd, Denmark, 12 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
| Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name of the Board member/Executive/Associated Person | Mathilde Rantzau | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Closely associated person to Thomas Rantzau, member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Purchase of shares | ||||
| c) | Price(s) and volume(s) | |||||
| Price(s) | Volume(s) | |||||
| DKK 891.20 | 11 shares | |||||
| d) | Aggregated information
| 11 Shares DKK 9,803.20 | ||||
| e) | Date of the transaction | 2024-08-09 | ||||
| f) | Place of the transaction | Nasdaq Copenhagen | ||||
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific
breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk
employs about 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
| Sina Meyer +45 3079 6656 azey@novonordisk.com | Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
| Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
Company announcement No 61 / 2024